

APO-MODAFINIL

modafinil tablets

PBS listed 1 July 2017

'a'- flagged with Modavigil*



Product Details

Strength	Product Description	Product Image
100 mg	White, round, biconvex tablets, engraved "MOD" over "100" on one side, "APO" on the other side	

NOTE: Packaging and tablet images are for illustrative purposes only and should be used as a guide.

Packaging Details

Strength	Pack Type	Pack Size	AUST R	Barcode	Pack Dimensions
100 mg	Blister	60	276420	9338475026265	97 x 57 x 29 mm

To find out more, call your Apotex Territory Manager
or our customer service team on **1800 APOTEX (1800 276 839)**

PBS Information: Authority required for the treatment of narcolepsy.

Please review the full Product Information (PI) before recommending; available from Apotex Medical Information on 1800 195 055 or www.ebs.tga.gov.au.

APO MODAFINIL Tablets Minimum Product Information. Indications: Excessive sleepiness assoc. with narcolepsy, mod severe chronic shift work sleep disorder (SWSD) where non pharmacological methods unsuccessful, inappropriate; adjunct to continuous +ve airway pressure in obstructive sleep apnoea/hypopnoea syndrome (OSAHS). **Contraindications:** Hypersensitivity to modafinil or any other component of the product; pregnancy. **Precautions:** Monitor for psychiatric disorder incl. suicidality, incr. hostile behaviour; major anxiety; psychosis, depression, mania, agitation, insomnia, substance abuse history; bipolar disorder; hypertension; pre treatment ECG; previous drug induced multi organ hypersensitivity; history of CNS stimulant assoc. LVH, ischaemic ECG changes, chest pain, arrhythmia, mitral valve prolapse; CAD; recent MI; unstable angina; monitor OSAHS incl. CV pathology; maintain good sleep hygiene, not for sleep replacement; dose > 400 mg/day; ensure effective contraception; renal, severe hepatic impairment; elderly ≥ 65 yrs; lactation; children < 18 yrs. **Interactions:** Methylphenidate; triazolam; MAOIs; CYP2C9 substrates; CYP2C19 substrates; TCAs, SSRIs (in CYP2D6 deficient patients); CYP3A4 inducers, inhibitors, substrates. **Adverse effects:** Headache; back pain; flu syndrome; chest pain; chills; neck rigidity; hypertension; tachycardia; palpitation; vasodilatation; nausea; diarrhoea; dyspepsia; dry mouth; anorexia; constipation; abnormal liver function; flatulence; mouth ulceration; thirst; eosinophilia; oedema; nervousness; insomnia; anxiety; dizziness; depression; paraesthesia; somnolence; hypertonia; dyskinesia; hyperkinesia; agitation; confusion; tremor; emotional lability; vertigo; rhinitis; pharyngitis; lung disorder; epistaxis; asthma; sweating; herpes simplex; amblyopia; abnormal vision; taste perversion; eye pain; urine abnormality; haematuria; pyuria; see full PI. **Dosage:** Swallow whole, admin. as single dose in morning or 2 divided doses (morning, noon). Use lowest effective dose. Narcolepsy, OSAHS: initially 200 mg/day; may incr. by 100 mg/day; max. 400 mg/day. SWSD: 200 mg/day 1 hr before work. See full PI. **Based on PI last amended:** 20 March 2017.

*Data on file